The European Alliance for Personalised Medicine (EAPM) continues to strengthen its role as a trusted interface between science, policy, and healthcare systems across Europe, ensuring that innovation in personalised medicine translates into timely and equitable patient access.

Over the past year, EAPM has played a central role in shaping EU-level discussions on diagnostics, data, biotechnology, and equitable access to care. Through close engagement with the European Parliament, European Commission, Council Presidencies, and national authorities, EAPM has helped align scientific advances with policy frameworks that support real-world implementation.

In 2025, EAPM contributed to key policy files including the updating of EU Council Conclusions on Cancer Screening, the EU Biotech Act, the European Health Data Space, and the AI and HTA regulatory frameworks. Flagship events such as Every Second Counts: Modernising Cancer Screening reinforced the importance of prevention, early detection, and system readiness in delivering equitable innovation across Member States.

Looking ahead to 2026, EAPM will launch its flagship initiative Advancing Personalised Medicine: Pathways for Future Innovation, delivering comparative evidence on how health systems adopt advanced diagnostics, AI-enabled tools, and biotech innovations. The initiative will support EU policy implementation through comparative studies, country factsheets, and targeted policy recommendations, reinforcing Europe’s competitiveness while improving patient access.

Through high-level advocacy, scientific engagement, and cross-stakeholder collaboration, EAPM remains committed to ensuring that Europe’s scientific excellence becomes accessible, affordable, and equitable care for patients across all Member States.

See below for the full newsletter.